DUBLIN – Johnson & Johnson's vaccine subsidiary Crucell Holland BV and Bavarian Nordic A/S have entered a formal license and supply agreement to accelerate and scale up an ongoing collaboration with the NIH in the development of a combination Ebola virus vaccine regimen.